5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene

被引:32
作者
Fuerer, C [1 ]
Iggo, R [1 ]
机构
[1] ISREC, NCCR Mol Oncol, Oncogene Grp, CH-1066 Epalinges, Switzerland
关键词
colon cancer; cytosine deaminase; suicide gene; internal ribosome entry site; alternative splicing;
D O I
10.1038/sj.gt.3302148
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Clinical studies with oncolytic adenoviruses have shown that existing viruses are safe but lack efficacy. To selectively increase the toxicity of oncolytic adenoviruses targeting colon tumours, we have inserted the yeast cytosine deaminase gene (yCD) after the fibre gene in the major late transcript. yCD was expressed using either an internal ribosome entry site (IRES) or by alternative splicing of a new exon analogous to the Ad41 long fibre exon. The IRES-CD virus gave higher yCD expression on Western blots. Both approaches result in yCD expression restricted to the period after viral DNA replication. Viral burst size was reduced by less than similar to10-fold by 5-fluorocytosine (5-FC), showing that expression of yCD as a late gene is compatible with virus replication. Cytopathic effect assays in colon cancer cell lines showed that both yCD viruses have similar to10-fold increased toxicity in the presence of the prodrug 5-FC, which is converted to 5-fluorouracil (5-FU) by yCD. Toxicity was higher following addition of 5-FC immediately after infection. The largest gain in toxicity was seen in HT29 colon cancer cells, which are the least permissive colon cancer cells for the parental virus, indicating that the new 5-FC/yCD viruses may have broader applications for colon cancer therapy than their predecessors.
引用
收藏
页码:142 / 151
页数:10
相关论文
共 55 条
[1]
Multigene expression from a replicating adenovirus using native viral promoters [J].
Bauzon, M ;
Castro, D ;
Karr, M ;
Hawkins, LK ;
Hermiston, TW .
MOLECULAR THERAPY, 2003, 7 (04) :526-534
[2]
Bell John C., 2003, Cancer Cell, V4, P7, DOI 10.1016/S1535-6108(03)00170-3
[3]
Bernt KM, 2002, CANCER RES, V62, P6089
[4]
PACKAGING CAPACITY AND STABILITY OF HUMAN ADENOVIRUS TYPE-5 VECTORS [J].
BETT, AJ ;
PREVEC, L ;
GRAHAM, FL .
JOURNAL OF VIROLOGY, 1993, 67 (10) :5911-5921
[5]
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[6]
BROKER TR, 1981, DNA TUMOUR VIRUSES, P994
[7]
A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4 [J].
Brough, DE ;
Lizonova, A ;
Hsu, C ;
Kulesa, VA ;
Kovesdi, I .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6497-6501
[8]
Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway [J].
Brunori, M ;
Malerba, M ;
Kashiwazaki, H ;
Iggo, R .
JOURNAL OF VIROLOGY, 2001, 75 (06) :2857-2865
[9]
Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[10]
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase [J].
Chung-Faye, GA ;
Chen, MJ ;
Green, NK ;
Burton, A ;
Anderson, D ;
Mautner, V ;
Searle, PF ;
Kerr, DJ .
GENE THERAPY, 2001, 8 (20) :1547-1554